文献速递胃肠外科围术期管理与 ERAS

腹腔镜袖状胃切除术与Roux-en-Y胃旁路术10年减重、合并症及反流结局:SLEEVEPASS随机临床试验

Effect of Laparoscopic Sleeve Gastrectomy vs Roux-en-Y Gastric Bypass on Weight Loss, Comorbidities, and Reflux at 10 Years in Adult Patients With Obesity: The SLEEVEPASS Randomized Clinical Trial.
PubMed 文献 · JAMA Surg · 2022-01-01

SLEEVEPASS多中心等效性随机试验10年观察性随访,比较LSG与LRYGB治疗重度肥胖的长期结局。240例患者随机分组,10年随访时LRYGB的%EWL更高(平均差8.4,95%CI 3.1-13.6),高血压缓解更优,LSG术后食管炎更常见,但两种术式Barrett食管发生率相似且较低。

要点

  • 10年时LRYGB的%EWL较LSG高8.4(95%CI 3.1-13.6),两种术式减重不等效。
  • LRYGB高血压缓解率优于LSG(24% vs 8%,P=.04)。
  • LSG术后食管炎更常见(31% vs 7%,P<.001),Barrett食管两组相似(4% vs 4%)。

核心结论

  • 10年时LRYGB的%EWL高于LSG,两种术式在减重上不等效,但两者均能实现良好且可持续的减重。
  • LSG术后食管炎更常见,但Barrett食管累积发生率明显低于既往试验,且两种术式相似。

研究设计与样本

  • SLEEVEPASS多中心等效性随机临床试验的10年观察性随访,初始试验于2008年4月至2010年6月在芬兰进行,末次随访2021年1月27日。
  • 240例18至60岁重度肥胖患者随机接受LSG(n=121)或LRYGB(n=119),中位BMI 44.6。
  • 10年时167例女性(69.6%),平均(SD)年龄48.4(9.4)岁,平均(SD)基线BMI 45.9(6.0)。
  • 193/228例(85%)完成体重和合并症随访,176/228例(77%)接受胃镜检查。

主要发现

  • 10年时LSG后%EWL中位数(范围)为43.5%(2.1%-109.2%),LRYGB后为50.7%(1.7%-111.7%)。
  • LRYGB的%EWL平均估计值较LSG高8.4(95%CI 3.1-13.6),两种术式不等效。
  • 2型糖尿病缓解率LSG 26%、LRYGB 33%(P=.63),血脂异常19% vs 35%(P=.23),阻塞性睡眠呼吸暂停16% vs 31%(P=.30),均无统计学显著差异。
  • 高血压缓解LRYGB优于LSG(24% vs 8%,P=.04)。
  • 食管炎LSG更常见(31% vs 7%,P<.001),Barrett食管两组无统计学显著差异(4% vs 4%,P=.29)。

关键数值与推荐

  • 主要终点为5年%EWL,本分析聚焦10年结局并特别关注反流和Barrett食管。
  • 10年时LSG后%EWL中位数43.5%,LRYGB后50.7%,LRYGB平均高8.4(95%CI 3.1-13.6)。
  • 高血压缓解率LRYGB 24% vs LSG 8%(P=.04)。
  • 食管炎发生率LSG 31% vs LRYGB 7%(P<.001),Barrett食管4% vs 4%(P=.29)。

临床怎么用

  • 对于重度肥胖患者,LRYGB在10年减重和高血压缓解方面可能优于LSG,但两种术式均可实现可持续减重。
  • LSG术后应关注食管炎风险,必要时进行内镜监测。
  • 两种术式Barrett食管发生率相似且较低,不应以此作为选择术式的主要依据。

局限性

  • 为10年观察性随访,部分患者失访(体重和合并症随访完成率85%,胃镜检查完成率77%)。
  • 2例从未接受手术,10例非相关死亡。
  • 原文未报告其他局限性信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Long-term results from randomized clinical trials comparing laparoscopic sleeve gastrectomy (LSG) with laparoscopic Roux-en-Y-gastric bypass (LRYGB) are limited. OBJECTIVE: To compare long-term outcomes of weight loss and remission of obesity-related comorbidities and the prevalence of gastroesophageal reflux symptoms (GERD), endoscopic esophagitis, and Barrett esophagus (BE) after LSG and LRYGB at 10 years. DESIGN, SETTING, AND PARTICIPANTS: This 10-year observational follow-up evaluated patients in the Sleeve vs Bypass (SLEEVEPASS) multicenter equivalence randomized clinical trial comparing LSG and LRYGB in the treatment of severe obesity in which 240 patients aged 18 to 60 years with median body mass index of 44.6 were randomized to LSG (n = 121) or LRYGB (n = 119). The initial trial was conducted from April 2008 to June 2010 in Finland, with last follow-up on January 27, 2021. INTERVENTIONS: LSG or LRYGB. MAIN OUTCOMES AND MEASURES: The primary end point was 5-year percentage excess weight loss (%EWL). This current analysis focused on 10-year outcomes with special reference to reflux and BE. RESULTS: At 10 years, of 240 randomized patients (121 randomized to LSG and 119 to LRYGB; 167 women [69.6%]; mean [SD] age, 48.4 [9.4] years; mean [SD] baseline BMI, 45.9 [6.0]), 2 never underwent surgery and there were 10 unrelated deaths; 193 of the remaining 228 patients (85%) completed follow-up on weight loss and comorbidities, and 176 of 228 (77%) underwent gastroscopy. Median (range) %EWL was 43.5% (2.1%-109.2%) after LSG and 50.7% (1.7%-111.7%) after LRYGB. Mean estimate %EWL was not equivalent between the procedures; %EWL was 8.4 (95% CI, 3.1-13.6) higher in LRYGB. After LSG and LRYGB, there was no statistically significant difference in type 2 diabetes remission (26% and 33%, respectively; P = .63), dyslipidemia (19% and 35%, respectively; P = .23), or obstructive sleep apnea (16% and 31%, respectively; P = .30). Hypertension remission was superior after LRYGB (8% vs 24%; P = .04). Esophagitis was more prevalent after LSG (31% vs 7%; P < .001) with no statistically significant difference in BE (4% vs 4%; P = .29). The overall reoperation rate was 15.7% for LSG and 18.5% for LRYGB (P = .57). CONCLUSIONS AND RELEVANCE: At 10 years, %EWL was greater after LRYGB and the procedures were not equivalent for weight loss, but both LSG and LRYGB resulted in good and sustainable weight loss. Esophagitis was more prevalent after LSG, but the cumulative incidence of BE was markedly lower than in previous trials and similar after both procedures. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00793143.

来源:JAMA Surg,查看原文。版权归原作者所有。

引用

  1. Salminen P, Grönroos S, Helmiö M, et al. Effect of Laparoscopic Sleeve Gastrectomy vs Roux-en-Y Gastric Bypass on Weight Loss, Comorbidities, and Reflux at 10 Years in Adult Patients With Obesity: The SLEEVEPASS Randomized Clinical Trial. JAMA Surg. 2022. PMID: 35731535. doi:10.1001/jamasurg.2022.2229

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。